← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL VACCINES › Meningococcal vaccines
meningococcus A, purified polysaccharides antigen
J07AH01
Forms & Strengths
- Lyophilized powder for injection
- 10 mcg, 20 mcg, 50 mcg meningococcal A polysaccharide per 0.5 mL
Adult Dosing
- Single 0.5 mL dose
- Booster dose every 2-5 years if at continued risk
Pediatric Dosing
- Not recommended for infants under 1 year
- Single 0.5 mL dose for children 1-2 years
- Single 0.5 mL dose for children over 2 years
Indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A
- Use in individuals 1 year of age and older
- High-risk individuals such as lab workers, travelers to epidemic areas
Mechanism of Action
- Stimulates production of antibodies against meningococcal A polysaccharide
- Induces immunological memory
- Prevents invasive meningococcal disease by enhancing phagocytosis and bacterial killing
Contraindications
- Hypersensitivity to meningococcal A polysaccharide or other components
- Severe allergic reaction to previous dose
Adverse Reactions
- Pain, redness, and swelling at the injection site
- Fatigue, headache, and fever
- Nausea and vomiting
Drug Interactions
- May interfere with immune response to other vaccines
- Use with caution in patients receiving immunosuppressive therapy
Curated Content: Needs Vetting Before Put to Clinical Use